Extracellular Vesicles Enriched in hsa-miR-301a-3p and hsa-miR-1293 Dynamics in Clear Cell Renal Cell Carcinoma Patients: Potential Biomarkers of Metastatic Disease.
biomarkers
clear cell renal cell carcinoma
extracellular vesicles
microRNAs
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Jun 2020
02 Jun 2020
Historique:
received:
19
05
2020
accepted:
29
05
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
6
6
2020
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is the most aggressive subtype of kidney cancer and up to 40% of patients submitted to surgery with a curative intent will relapse. Thus, the aim of this study was to analyze the applicability of an Extracellular vesicle (EV) derived miRNA profile as potential prognosis biomarkers in ccRCC patients. We analyzed a nine-miRNA profile in plasma EVs from 32 ccRCC patients with localized disease (before and after surgery) and in 37 patients with metastatic disease. We observed that the levels of EV-derived hsa-miR-25-3p, hsa-miR-126-5p, hsa-miR-200c-3p, and hsa-miR-301a-3p decreased after surgery, whereas hsa-miR-1293 EV-levels increased. Furthermore, metastatic patients presented higher levels of hsa-miR-301a-3p and lower levels of hsa-miR-1293 when compared to patients with localized disease after surgery. Functional enrichment analysis of the targets of the four miRNAs that decreased after surgery resulted in an enrichment of terms related to cell cycle, proliferation, and metabolism, suggesting that EV-miRNA enrichment in the presence of the tumor could represent an epigenetic mechanism to sustain tumor development. Taken together, these results suggest that EVs content varies depending on the presence or absence of the disease and that an increase of EV-derived hsa-miR-301a-3p, and decrease of EV-derived hsa-miR-1293, may be potential biomarkers of metastatic ccRCC.
Identifiants
pubmed: 32498409
pii: cancers12061450
doi: 10.3390/cancers12061450
pmc: PMC7352268
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Regional Development Fund
ID : NORTE-01-0247-FEDER-033399
Organisme : Instituto Português de Oncologia do Porto
ID : CI-IPOP-21-2015
Références
Cell Physiol Biochem. 2014;34(2):213-43
pubmed: 25034869
J Extracell Vesicles. 2013 Mar 05;2:
pubmed: 24009895
Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2175-2185
pubmed: 28579513
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):64-77
pubmed: 29175553
Semin Liver Dis. 2015 Feb;35(1):3-11
pubmed: 25632930
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Nat Methods. 2013 Nov;10(11):1046-7
pubmed: 24037243
Nature. 2008 Sep 4;455(7209):64-71
pubmed: 18668037
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812
J Oncol. 2016;2016:5035127
pubmed: 27019657
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Curr Pharm Des. 2009;15(33):3895-903
pubmed: 19671042
Front Oncol. 2019 May 08;9:357
pubmed: 31139560
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
Nat Rev Urol. 2010 May;7(5):277-85
pubmed: 20448661
J Cancer. 2015 Oct 20;6(12):1260-75
pubmed: 26640587
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
Eur Urol Focus. 2018 Apr;4(3):412-419
pubmed: 28753793
Mol Ther. 2020 Jun 3;28(6):1494-1505
pubmed: 32320642
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Mol Cancer. 2019 Apr 11;18(1):86
pubmed: 30975145
Ai Zheng. 2002 Jun;21(6):582-7
pubmed: 12452054
Eur J Cancer. 2019 Feb;108:33-40
pubmed: 30616146
BMC Bioinformatics. 2011 Nov 09;12:436
pubmed: 22070249
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
World J Urol. 2016 Aug;34(8):1081-6
pubmed: 26847337
Nucleic Acids Res. 2016 Jul 27;44(13):6019-35
pubmed: 27317695
Cardiovasc Pathol. 2020 Jul - Aug;47:107208
pubmed: 32097731
Cancers (Basel). 2020 Jan 27;12(2):
pubmed: 32012717
J Cell Mol Med. 2019 Oct;23(10):6755-6765
pubmed: 31342628
Cancer Treat Rev. 2012 Dec;38(8):996-1003
pubmed: 22330762
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Cell Metab. 2018 Nov 6;28(5):793-800.e2
pubmed: 30146487
Mol Cell Biochem. 2013 Dec;384(1-2):1-6
pubmed: 23943285
BMC Res Notes. 2017 Nov 29;10(1):641
pubmed: 29187235
J Kidney Cancer VHL. 2014 Dec 24;1(8):84-98
pubmed: 28326253
World J Methodol. 2013 Mar 26;3(1):11-8
pubmed: 25237619
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
J Pathol. 2010 Jun;221(2):125-38
pubmed: 20225241
Oncotarget. 2017 Nov 15;8(66):109877-109888
pubmed: 29299115
Int J Mol Sci. 2019 Apr 13;20(8):
pubmed: 31013896
Biotechnol Lett. 2004 Mar;26(6):509-15
pubmed: 15127793
Eur Urol Focus. 2019 Sep;5(5):857-866
pubmed: 29525381
Pharmacogenomics. 2013 Nov;14(14):1793-803
pubmed: 24192126
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Int J Cancer. 2020 Feb 15;146(4):1052-1063
pubmed: 31259424
Mol Aspects Med. 2018 Apr;60:15-26
pubmed: 29196097
Cancer Discov. 2019 Aug;9(8):1006-1021
pubmed: 31088840
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1278-1283
pubmed: 30017193
J Cell Biochem. 2018 Oct 10;:
pubmed: 30304555
Eur Urol Focus. 2016 Jun;2(2):210-218
pubmed: 28723537
Biochem Pharmacol. 2011 Nov 15;82(10):1416-29
pubmed: 21864506
Nat Commun. 2014 May 29;5:3887
pubmed: 24871328
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Nucleic Acids Res. 2002 Apr 1;30(7):1575-84
pubmed: 11917018
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
J Genet Genomics. 2015 Jul 20;42(7):343-53
pubmed: 26233890
Genomics Proteomics Bioinformatics. 2009 Dec;7(4):147-54
pubmed: 20172487
Annu Rev Biochem. 2001;70:247-79
pubmed: 11395408
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Mol Carcinog. 2018 Feb;57(2):295-302
pubmed: 28981169